Engineers TV

As a member of Engineers Ireland you have access to Engineers TV, which contains over 700 presentations, technical lectures, courses and seminar recordings as well as events and awards footage and interviews.

It is no secret that filling skilled roles in the pharmaceutical and biotech industries in Ireland presents significant challenges. As a complete solutions provider to these sectors in the areas of validation and calibration Ellab is all too aware of the competitive recruitment landscape.

At Ellab, the belief in employee potential is paramount. It views developing a strong company culture backed by values as essential for fostering employee engagement, loyalty, and productivity.

Moreover, Ellab understands that a thriving work culture goes beyond traditional notions of professional development. It encompasses a holistic approach that prioritises employee wellbeing and helps support a work-life balance.

Always working on new initiatives

Ellab’s HR manager in Ireland, Aoife Keaney, says the company is always working on new initiatives and ways to support its employees. “We’re currently developing dedicated career pathways across the company so when you join us you will be able to see the opportunities for upskilling, career growth and promotion that lie ahead.”  

But the company isn’t just focusing on being highly competitive in terms of salary and benefits, it is also committed to making sure Ellab is a supportive work environment where people from diverse backgrounds can all thrive personally as well as professionally.

In an industry historically dominated by male representation, Ellab recognises the need to remove barriers and tackle stereotypes for under-represented groups, particularly women, to thrive and excel.

The team in Ireland see diversity among the workforce as a catalyst for creativity, collaboration, and problem-solving that will drive innovation and propel Ellab to new heights of success in an increasingly competitive market landscape.

Providing engineers in Ireland with opportunities to work abroad and gain highly beneficial international experience is also important in the drive to attract and retain the best talent. “For us borders are not a barrier,” said Paul O’Hare, managing director of Ellab’s Irish division.

“On a global level we’re currently developing a streamlined field service offering so that our teams of engineers and technicians can move seamlessly to support colleagues in other markets.”

Improve collaboration across borders

At present the Irish team is providing engineers and technicians for projects in Denmark and are in discussion with colleagues in the US and UK about how to improve collaboration across borders.

The company firmly believes this international exposure enhances skills, fosters cultural understanding, and promotes innovation, which ultimately enriches the engineer's career while contributing to the team's global perspective and success.

On a global level the company has grown rapidly in recent years with a number of important M&As across Europe and the US. Supporting these teams to integrate is an ongoing process and will be important for Ellab’s ability to attract, support and retain talent.

At the heart of Ellab's ethos lies a profound belief in the potential of its employees. Recognising that personal and professional development are intrinsic to individual and organisational success, Ellab is developing a multifaceted approach to support its workforce to thrive and make a meaningful impact in their field.

 

Ellab ethos — a company that prioritises employee wellbeing and work-life balance

Established in 1949, and headquartered in Hillerod, north of Copenhagen, Ellab's mission is to reduce time-to-market and mitigate product loss risks for global biotech and pharma companies. This mission is achieved through a comprehensive offering, including onsite validation and calibration management, monitoring systems, consulting, and a continually expanding portfolio of products. 

Since introducing their first thermometers in the 1950s, they have developed an extensive product range, from wireless data loggers to thermocouple systems designed for thermal validation processes and environmental wireless monitoring solutions. 

In recent years, onsite services have gained increasing importance for the company.

Direct presence

Ellab's slogan, 'Global Knowledge with Local Reach', perfectly encapsulates its strategy of establishing a direct presence in key markets through successful mergers and acquisitions (M&As).  

The company began establishing its presence in Ireland in 2020 with the acquisition of Co. Meath based instrumentation products and services supplier, Instrument Technology Ltd, and Cork-based thermal qualification and validation service provider, QualUs.

Its presence was further expanded in 2022 with the acquisitions of Autocal, a Dublin-based validation services provider and CalX, a calibration services provider, based in Co Meath.   

The fact that the owners of the four previous companies – Peter Keane, Gerard Collins, Paul O’Hare, Kevin Davis, Claire McMahon, and Willie McMahon –stayed on in leadership roles helped to both ensure a smooth transition and retain decades of industry experience and knowledge.     

As a trusted global partner to the world's top 20 biotech companies and the world's top 40 pharma companies, Ellab is well positioned in terms of industry-leading expertise and the company’s skilled validation and calibration engineers and technicians are making a significant impact across numerous sites in Ireland.

"2023 was a very busy year for us," remarks Paul O’Hare, managing director of Ellab Ireland. "We saw tremendous growth within the Irish market, and we successfully merged four separate companies into one cohesive unit."

Complete solutions provider

Ellab's standout offering in the Irish market lies in being a complete solutions provider, covering both products and services with an emphasis on managed services where they go beyond just performing required tasks.

For example, in the area of calibrations, Ellab don’t just perform calibrations as required, they also manage the entire process from notifying the client when calibrations are due to ensuring all necessary documentation is uploaded and available online at the touch of a button before their team even leave the site.    

Looking ahead to 2024, Paul O'Hare anticipates even more activity for Ellab Ireland, “we have plans to substantially expand our operations in Ireland over the coming years with a number of significant developments in the pipeline here”.

Amid this growth however, the dedication to maintaining the highest quality standards remains unwavering. Ellab is committed to offering top-tier equipment, employing the best engineers and technicians, and prioritising continuous training and development for its teams, to ensure clients receive the best possible service, both onsite and from support personnel. 

There appears to be exciting developments ahead for Ellab’s Irish operation.

Ellab: Global knowledge with local reach

The European Commission has adopted a recommendation on critical technology areas for the EU's economic security, for further risk assessment with member states. This recommendation stems from the Joint Communication on a European Economic Security Strategy that put in place a comprehensive strategic approach to economic security in the EU.

This recommendation relates to the assessment of one of four types of risks in that comprehensive approach, namely technology risk and technology leakage. The risk assessment will be objective in character, and neither its results nor any follow-up measures can be anticipated at this stage.

In the recommendation, the commission puts forward a list of 10 critical technology areas. These technology areas were selected based on the following criteria:

  • Enabling and transformative nature of the technology: the technologies' potential and relevance for driving significant increases of performance and efficiency and/or radical changes for sectors, capabilities, etc;
  • The risk of civil and military fusion: the technologies' relevance for both the civil and military sectors and its potential to advance both domains, as well as risk of uses of certain technologies to undermine peace and security;
  • The risk the technology could be used in violation of human rights: the technologies' potential misuse in violation of human rights, including restricting fundamental freedoms.

Collective risk assessments with member states

Out of the 10 critical technology areas, the recommendations identifies four technology areas that are considered highly likely to present the most sensitive and immediate risks related to technology security and technology leakage:

  1. Advanced Semiconductors technologies (microelectronics, photonics, high frequency chips, semiconductor manufacturing equipment).
  2. Artificial Intelligence technologies (high performance computing, cloud and edge computing, data analytics, computer vision, language processing, object recognition).
  3. Quantum technologies (quantum computing, quantum cryptography, quantum communications, quantum sensing and radar).
  4. Biotechnologies (techniques of genetic modification, new genomic techniques, gene-drive, synthetic biology).

The commission recommends that member states, together with the commission, initially conduct collective risk assessments of these four areas by the end of this year.

The recommendation includes some guiding principles to structure the collective risk assessments, including consultation of the private sector and protection of confidentiality.

In deciding on proposals for further collective risk assessments with member states on one or more of the listed additional technology areas, or subsets thereof, the commission will take into account ongoing or planned actions to promote or partner in the technology area under consideration.

More generally, the commission will bear in mind that measures taken to enhance the competitiveness of the EU in the relevant areas can contribute to reducing certain technology risks.

EU recommends risk assessments for four critical tech areas: advanced semiconductors, AI, quantum and biotechnologies

"This technology is not alive," says Laia Mogas-Soldevila. "It is living-like."

The distinction is an important one for the assistant professor at the Stuart Weitzman School of Design, for reasons both scientific and artistic. With a doctorate in biomedical engineering, several degrees in architecture, and a devotion to sustainable design, Mogas-Soldevila brings biology to everyday life, creating materials for a future built halfway between nature and artifice.

Collaboration between designers, engineers and biologists

The architectural technology she describes is unassuming at first look: A freeze-dried pellet, small enough to get lost in your pocket. But this tiny lump of matter – the result of more than a year's collaboration between designers, engineers and biologists – is a biomaterial that contains a 'living-like' system.

When touched by water, the pellet activates and expresses a glowing protein, its fluorescence demonstrating that life and art can harmonise into a third and very different thing, as ready to please as to protect. Woven into lattices made of flexible natural materials promoting air and moisture flow, the pellets form striking interior design elements that could one day keep us healthy.

The figure above demonstrates (A) design for support lattices for the team’s innovative bioactive sites, (B) a ribbon-like geometry for hanging and (C, D) how these structures may be integrated into indoor environments to biologically sense and react to air.

"We envision them as sensors," explains Mogas-Soldevila. "They may detect pathogens, such as bacteria or viruses, or alert people to toxins inside their home. The pellets are designed to interact with air. With development, they could monitor or even clean it."

For now, they glow, a triumphant first stop on the team's roadmap to the future. The fluorescence establishes that the lab's biomaterial manufacturing process is compatible with the leading-edge cell-free engineering that gives the pellets their life-like properties.

A rapidly expanding technology, cell-free protein expression systems allow researchers to manufacture proteins without the use of living cells.

Cell-free

Gabrielle Ho, PhD candidate in the Department of Bioengineering and co-leader of the project, explains how the team's design work came to be cell-free, a technique rarely explored outside of lab study or medical applications.

"Typically, we'd use living E. coli cells to make a protein," says Ho. "E. coli is a biological workhorse, accessible and very productive. We'd introduce DNA to the cell to encourage expression of specific proteins. But this traditional method was not an option for this project. You can't have engineered E. coli hanging on your walls."

Cell-free systems contain all the components a living cell requires to manufacture protein – energy, enzymes and amino acids – and not much else. These systems are therefore not alive. They do not replicate, and neither can they cause infection. They are 'living-like', designed to take in DNA and push out protein in ways that previously were only possible using living cells.

"One of the nicest things about these materials not being alive," says Mogas-Soldevila, "is that we don't need to worry about keeping them that way."

Unlike living cells, cell-free materials don't need a wet environment or constant monitoring in a lab. The team's research has established a process for making these dry pellets that preserves bioactivity throughout manufacturing, storage and use.

Bioactive, expressive and programmable, this technology is designed to capitalise on the unique properties of organic materials.

Mogas-Soldevila, whose lab focuses exclusively on biodegradable architecture, understands the value of biomaterials as both environmentally responsible and aesthetically rich.

"Architects are coming to the realisation that conventional materials – concrete, steel, glass, ceramic, etc – are environmentally damaging and they are becoming more and more interested in alternatives to replace at least some of them. Because we use so much, even being able to replace a small percentage would result in a significant reduction in waste and pollution."

Sustainable advantages

Her lab's signature materials – biopolymers made from shrimp shells, wood pulp, sand and soil, silk cocoons, and algae gums – lend qualities over and above their sustainable advantages.

"My obsession is diagnostic, but my passion is playfulness," says Mogas-Soldevila. "Biomaterials are the only materials that can encapsulate this double function observed in nature."

This multivalent approach benefited from the help of Penn Engineering's George H. Stephenson Foundation Educational Laboratory & Bio-MakerSpace, and the support of its director, Sevile Mannickarottu.

In addition to contributing essential equipment and research infrastructure to the team, Mannickarottu was instrumental in enabling the interdisciplinary relationships that led the team to success, introducing Ho to the DumoLab Research team collaborators. These include Mogas-Soldevila, Camila Irabien, a Penn Biology major who provided crucial contributions to experimental work, and Fulbright design fellow Vlasta Kubušová, who co-led the project during her time at Penn and who will continue fuelling the project's next steps.

The cell-free manufacturing and design research required unique dialogues between science and art, categories that Ho believed to be entirely separate before embarking on this project.

"I learnt so much from the approach the designers brought to the lab," says Ho. "Usually, in science, we have a specific problem or hypothesis that we systematically work towards."

Camila Irabien and Dionne Yeung work in the Stephenson Foundation Educational Laboratory and Bio-MakerSpace.

But in this collaboration, things were different. Open-ended. The team sought a living-like platform that does sensing and tells people about interactive matter. They needed to explore, step by step, how to get there.

"Design is only limited by imagination. We sought a technology that could help build towards a vision, and that turned out to be cell-free," says Ho.

"For my part," says Mogas-Soldevila, "it was inspiring to witness the rigour and attention to constraints that bioengineering brings."

Constraints

The constraints were many – machine constraints, biological constraints, financial constraints and space constraints.

"But as we kept these restrictions in play," she continues, "we asked our most pressing creative questions. Can materials warn us of invisible threats? How will humans react to these bioactive sites? Will they be beautiful? Will they be weird? Most importantly, will they enable a new aesthetic relationship with the potential of bio-based and bioactive matter?"

Down the line, the cell-free pellets and biopolymer lattices could drape protectively over our interior lives, caring for our mental and physical health. For now, research is ongoing, the poetry of design energised by constraint, the constraint of engineering energised by poetry.

The art and science of living-like architecture

Voigt Lab's work could eventually replace cereal crops’ need for nitrogen from chemical fertilisers.

As food demand rises due to growing and changing populations around the world, increasing crop production has been a vital target for agriculture and food systems researchers who are working to ensure there is enough food to meet global need in the coming years.

One MIT research group mobilising around this challenge is the Voigt lab in the Department of Biological Engineering, led by Christopher Voigt, the Daniel IC Wang Professor of Advanced Biotechnology at MIT.

For the past four years, the Abdul Latif Jameel Water and Food Systems Lab (J-WAFS) has funded Voigt with two J-WAFS Seed Grants. With this support, Voigt and his team are working on a significant and long-standing research challenge: transform cereal crops so they are able to fix their own nitrogen.

Chemical fertiliser: how it helps and hurts


Nitrogen is a key nutrient that enables plants to grow. Plants like legumes are able to provide their own through a symbiotic relationship with bacteria that are capable of fixing nitrogen from the air and putting it into the soil, which is then drawn up by the plants through their roots.

Other types of crops — including major food crops such as corn, wheat, and rice — typically rely on added fertilisers for nitrogen, including manure, compost, and chemical fertilisers. Without these, the plants that grow are smaller and produce less grain.

More than 3.5 billion people today depend on chemical fertilisers for their food. A total of 80% of chemical nitrogen fertilisers today are made using the Haber-Borsch process, which involves transforming nitrile gas into ammonia.

While nitrogen fertiliser has boosted agriculture production in the last century, this has come with some significant costs.

First, the Haber-Borsch process itself is very energy- and fossil fuel-intensive, making it unsustainable in the face of a rapidly changing climate.

Second, using too much chemical fertiliser results in nitrogen pollution. Fertiliser runoff pollutes rivers and oceans, resulting in algae blooms that suffocate marine life.

Cleaning up this pollution and paying for the public health and environmental damage costs the US $157 billion annually.

Third, when it comes to chemical fertilisers, there are problems with equity and access. These fertilisers are made in the northern hemisphere by major industrialised nations, where postash, a main ingredient, is abundant.

However, transportation costs are high, especially to countries in the southern hemisphere. So, for farmers in poorer regions, this barrier results in lower crop yield.

These environmental and societal challenges pose large problems, yet farmers still need to apply nitrogen to maintain the necessary agriculture productivity to meet the world’s food needs, especially as population and climate change stress the world’s food supplies. So, fertilisers are and will continue to be a critical tool.

But, might there be another way?

The bacterial compatability of chloroplasts and mitochondria


This is the question that drives researchers in the Voigt lab, as they work to develop nitrogen-fixing cereal grains. The strategy they have developed is to target the specific genes in the nitrogen-fixing bacteria that operate symbiotically with legumes, called the nif genes.

These genes cause the expression of the protein structures (nitrogenase clusters) that fix nitrogen from the air. If these genes were able to be successfully transferred and expressed in cereal crops, chemical fertilisers would no longer be needed to add needed nitrogen, as these crops would be able to obtain nitrogen themselves.

This genetic engineering work has long been regarded as a major technical challenge, however. The nif pathway is very large and involves many different genes. Transferring any large gene cluster is itself a difficult task, but there is added complexity in this particular pathway.

The nif genes in microbes are controlled by a precise system of interconnected genetic parts. In order to successfully transfer the pathway’s nitrogen-fixing capabilities, researchers not only have to transfer the genes themselves, but also replicate the cellular components responsible for controlling the pathway.

This leads into another challenge. The microbes responsible for nitrogen fixation in legumes are bacteria (prokaryotes), and, as explained by Eszter Majer, a postdoc in the Voigt lab who has been working on the project for the past two years, “the gene expression is completely different in plants, which are eukaryotes”.

For example, prokaryotes organise their genes into operons, a genetic organisation system that does not exist in eukaryotes such as the tobacco leaves the Voigt is using in its experiments. Reengineering the nif pathway in a eukaryote is tantamount to a complete system overhaul.

The Voigt lab has found a workaround: rather than target the entire plant cell, they are targeting organelles within the cell — specifically, the chloroplasts and the mitochondria. Mitochondria and chloroplasts both have ancient bacterial origins and once lived independently outside of eukaryotic cells as prokaryotes.

Millions of years ago, they were incorporated into the eukaryotic system as organelles. They are unique in that they have their own genetic data and have also maintained many similarities to modern-day prokaryotes.

As a result, they are excellent candidates for nitrogenase transfer. Majer says: “It’s much easier to transfer from a prokaryote to a prokaryote-like system than reengineer the whole pathway and try to transfer to a eukaryote.”

Beyond gene structure, these organelles have additional attributes that make them suitable environments for nitrogenase clusters to function. Nitrogenase requires a lot of energy to function and both chloroplasts and mitochondria already produce high amounts energy — in the form of ATP — for the cell.

Nitrogenase is also very sensitive to oxygen and will not function if there is too much of it in its environment. However, chloroplasts at night and mitochondria in plants have low-oxygen levels, making them an ideal location for the nitrogenase protein to operate.

An international team of experts


While the team found devised an approach for transforming eukaryotic cells, their project still involved highly technical biological engineering challenges. Thanks to the J-WAFS grants, the Voigt lab has been able to collaborate with two specialists at overseas universities to obtain critical expertise.

One was Luis Rubio, an associate professor focusing on the biochemistry of nitrogen fixation at the Polytechnic University of Madrid, Spain. Rubio is an expert in nitrogenase and nitrogen-inspired chemistry.

Transforming mitochondrial DNA is a challenging process, so the team designed a nitrogenase gene delivery system using yeast. Yeast are easy eukaryotic organisms to engineer and can be used to target the mitochondria.

The team inserted the nitrogenase genes into the yeast nuclei, which are then targeted to mitochondria using peptide fusions. This research resulted in the first eukaryotic organism to demonstrate the formation of nitrogenase structural proteins.

The Voigt lab also collaborated with Ralph Bock, a chloroplast expert from the Max Planck Institute of Molecular Plant Physiology in Germany.

He and the Voigt team have made great strides toward the goal of nitrogen-fixing cereal crops; the details of their recent accomplishments advancing the field crop engineering and furthering the nitrogen-fixing work will be published in the coming months.

Continuing in pursuit of the dream


The Voigt lab, with the support of J-WAFS and the invaluable international collaboration that has resulted, was able to obtain groundbreaking results, moving us closer to fertiliser independence through nitrogen-fixing cereals.

They made headway in targeting nitrogenase to mitochondria and were able to express a complete NifDK tetramer — a key protein in the nitrogenase cluster — in yeast mitochondria. Despite these milestones, more work is yet to be done.

“The Voigt lab is invested in moving this research forward in order to get ever closer to the dream of creating nitrogen-fixing cereal crops,“ says Chris Voigt.

With these milestones under their belt, these researchers have made great advances, and will continue to push towards the realisation of this transformative vision, one that could revolutionize cereal production globally.

Making real a biotechnology dream: nitrogen-fixing cereal crops

Minister for Business, Enterprise and Innovation Heather Humphreys has launched 'Ireland – the Global BioPharmaChem Location of Choice', the five-year strategy of BioPharmaChem Ireland (BPCI), the Ibec group that represents biopharmaceutical and chemical manufacturing, at Government Buildings. Minister Humphreys said: “Ireland’s continued success in biopharmaceutical manufacturing is a fitting testament to the innovative companies that are based here and to the commitment of our talented people.

'Clear vision for future development of industry'


"In launching this new strategy, BioPharmaChem Ireland has built on those strengths and set out a clear vision for the future development of the industry over the next number of years. "As minister, I am very aware of the importance of this sector to our economy and I look forward to working together to maintain and grow Ireland’s position as a global leader in biopharma manufacturing.” BPCI director Matt Moran, said: “The phenomenal growth of the sector in Ireland is no accident – it has been achieved by world class companies who continually focus on innovation and through delivering new and improved products to the market. "We have always tried to stay at the cutting edge including a campaign to encourage Government to focus on biotechnology in the mid-1990s. "This has paid dividends and over the last decade alone, in excess of €10 billion euro has been invested by the industry in biomanufacturing operations in Ireland. Looking forward, we need to focus on the next phase of development including the digitisation of manufacturing and advanced therapeutics.”

'Bring the industry to its next phase of innovation'


BPCI chair Patricia Quane, VP and general manager, Astellas Ireland, said: “The strategy is designed to bring the industry to its next phase of innovation. We are proud of our international reputation with all of the top 10 global biopharma companies operating in this country.” Since its foundation in 1994, BPCI has overseen an extraordinary growth in the industry with Ireland’s exports from the sector increasing from €6 billion to €73 billion in 2018. In addition, employment increased during the period from 18,000 to over 30,000, with the result that Ireland is regarded internationally as being one of the industry’s most important manufacturing locations in the world.

BioPharmaChem Ireland’s sector strategy 2019-2023 unveiled

Theme picker